Lucid Diagnostics Inc

NASDAQ:LUCD 3:59:50 PM EDT

7.84

-0.12 (-1.51%)

Market Cap (Intraday)	290.01M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.2 Million
Adjusted EPS	-$0.18

See more estimates

10-Day MA	$8.43
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Lucid Diagnostics Inc Stock, NASDAQ:LUCD

One Grand Central Place, Suite 4600, New York, New York 10165

United States of America

Phone: +1.212.949.4319

Number of Employees:

http://www.luciddx.com

Description

Lucid Diagnostics, Inc. develops medical testing devices. It is a commercial-stage medical diagnostics technology company which focuses on gastroesophageal reflux disease (GERD), acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The company's products include EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus without the need for endoscopy and EsoGuard is a laboratory developed test which analyzes methylated biomarkers. The company was founded on May 8, 2018 and is headquartered in New York, NY.